Protagenic Therapeutics, Inc.\new: Form 10-QT, filed Sep 10, 2025
Filed with the SEC on Sep 10, 2025 and accepted by EDGAR at Sep 10, 2025, 16:06 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $0 | us-gaap:Revenues |
| Research and development | 3 months2025-04-01 to 2025-06-30 | $394.1k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$2.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$5.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | −$1.37 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | −$1.37 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 3,701,226 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2025-04-01 to 2025-06-30 | −$1.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-06-30 | $4.1m | us-gaap:Cash |
| Current assets | At period end2025-06-30 | $4.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $6.5m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $10.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $10.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-30 | −$4.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001641172-25-027041. Last ingested by Listed: Nov 6, 2026, 14:34 ET. Listed shows no prices and gives no investment advice.